Amplia Therapeutics (ASX:ATX) EBITDA Margin %: 0.00% (As of Mar. 2026)


ASX:ATX Amplia Therapeutics Ltd ASX:ATX
36 GF Score
Price A$0.14
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics EBITDA Margin %?

Amplia Therapeutics ASX:ATX +8.00% 36 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Amplia Therapeutics ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Amplia Therapeutics's EBITDA for the six months ended in Mar. 2026 was A$-3.46 Mil. Amplia Therapeutics's Revenue for the six months ended in Mar. 2026 was A$0.00 Mil. Therefore, Amplia Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Amplia Therapeutics  (ASX:ATX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Amplia Therapeutics EBITDA Margin % Related Terms

Amplia Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics EBITDA Margin % Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:ATX vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Amplia Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's EBITDA Margin % falls into.


ASX:ATX
36GF Score
Amplia Therapeutics Ltd ASX:ATX
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Amplia Therapeutics's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-7.598/0
= %

Amplia Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.462/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Amplia Therapeutics (ASX:ATX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amplia Therapeutics and its competitors. According to the industry distribution chart, Amplia Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Amplia Therapeutics' EBITDA Margin % too high?
Amplia Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Amplia Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Amplia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score

Get the complete analysis for ASX:ATX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price